AtriCure (ATRC) reported $153.6 million in revenue for the quarter ended June 2026, representing a year-over-year increase of ...

Q2 2026 earnings call recap: revenue growth, margin expansion, raised 2026 guidance, and BoxX-NoAF trial progress—read key takeaways now.

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago. These figures are ...

Key Points Interested in AtriCure, Inc.? Here are five stocks we like better. AtriCure posted strong Q2 2026 results, with ...

AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you ...

The "AtriCure Inc (ATRC) - Product Pipeline Analysis, 2025 Update" company profile has been added to ResearchAndMarkets.com's offering. This report is a source for data, analysis, and actionable ...

Sven Wehrwein, a member of the Board of Directors at AtriCure (NASDAQ:ATRC), exercised 10,000 non-qualified stock options and immediately sold the underlying shares in derivative transactions on ...

Investors might want to bet on AtriCure (ATRC), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H ...

AtriCure Inc. (NASDAQ: ATRC) has received regulatory clearance to begin U.S. sales of its AtriClip device, which protects against blood clots during certain heart procedures. The news sent AtriCure’s ...

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and ...

With a key FDA approval in hand for its cardiac ablation technology, device maker AtriCure (NASDAQ:ATRC) has its sights set on grabbing market share from industry giant Medtronic (NYSE:MDT). In ...